Stockholm, Sweden – September 4, 2025 – Stratipath, a leader in AI-based precision diagnostics for cancer, today announced an integration and distribution partnership with PathAI. With this collaboration, Stratipath Breast will be available within PathAI’s AISight® Dx Image Management System (IMS), enabling laboratories and clinicians worldwide to access cutting-edge AI-powered prognostic risk profiling easily within their diagnostic workflow.
Revolutionising Breast Cancer Prognostic Risk Profiling with AI
Stratipath Breast is the first CE-IVD marked AI-based solution for prognostic risk profiling of breast cancer using routine histopathology slides. It provides an alternative to traditional gene expression tests, which are often associated with high costs, long turnaround times, and limited accessibility. Stratipath Breast delivers results within one hour, ready to support clinical decisions at the tumour board.
Stratipath Breast enables healthcare providers to:
- Support treatment decisions with actionable risk profiling
- Make precision diagnostics available to more patients
By integrating Stratipath Breast into AISight Dx, pathologists will be able to leverage its validated results directly within routine case review. This seamless workflow eliminates the need for additional logistics, equipment, or handling—making access to precision diagnostics faster, more efficient, and more equitable.
“We are proud to partner with PathAI to bring Stratipath Breast into the AISight Dx system,” said Fredrik Wetterhall, CEO and Co-founder of Stratipath. “Together, we are scaling access to a transformative solution that delivers rapid and reliable prognostic insights, helping ensure every breast cancer patient can receive the right treatment at the right time.”
“With this partnership, PathAI continues to build the most comprehensive CE-IVD digital pathology ecosystem,” said Andy Beck, MD, PhD, Co-founder and CEO of PathAI. “Our expanded AI portfolio now including Stratipath Breast brings validated prognostic results directly into the hands of pathologists via AISight Dx, accelerating adoption and reinforcing trust in digital workflows.
Representatives from Stratipath and PathAI will be present at the European Congress of Pathology in Vienna. If you would like to hear more about the partnership, please reach out to us for meetings or discussions.
About Stratipath
Stratipath is an AI company dedicated to revolutionising cancer treatment decisions and enhancing patient outcomes by assisting physicians in delivering the right treatment to every patient. Its pioneering AI-based diagnostic software platform transforms tissue sample analysis, enabling breakthrough insights for enhanced and faster patient stratification across healthcare, clinical trials, and drug development. Founded as a spin-out of Karolinska Institutet in Stockholm, Sweden, Stratipath builds on years of groundbreaking research and clinical validation. For more information, please visit www.stratipath.com.
About PathAI
PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit pathai.com
AISight® Dx is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland and FDA-cleared for primary diagnosis in the US.